Kennedy Capital Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Kennedy Capital Management’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-96,901	Closed	-$1.24M	–	744
2018 Q4	$1.24M	Sell	96,901 -211	-0.2%	-$3.2K	0.03%	591
2018 Q3	$1.58M	Sell	97,112 -51,415	-35%	-$735K	0.03%	598
2018 Q2	$1.92M	Sell	148,527 -34,312	-19%	-$464K	0.04%	605
2018 Q1	$2.28M	Buy	182,839 +83,927	+85%	+$1.02M	0.04%	583
2017 Q4	$1.38M	Buy	+98,912	New	+$1.45M	0.02%	645

Other funds holding OXFD

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Kennedy Capital Management's OXFD Position: Q1 2019 in Review

Kennedy Capital Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2019, closing a stake of 96,901 shares — an estimated $1.24M sold.

Kennedy Capital Management first reported a position in OXFD in Q4 2017 and held it in 5 quarters. The position peaked at $2.28M in Q1 2018. 92 funds tracked by Wall St. Rank hold OXFD as of Q1 2019.

Kennedy Capital Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2019 after selling out during the quarter.
Kennedy Capital Management sold 96,901 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2019, an estimated $1.24M.
Kennedy Capital Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2017 and held it in 5 quarters.
Kennedy Capital Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $2.28M in Q1 2018.
92 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2019.

Based on Kennedy Capital Management's 13F filing for Q1 2019, filed 13 May 2019.